pharmaceutical company, improving the potency and safety of potent molecules. Our advanced R&D facilities in Texas foster a prime environment for our scientists to create cutting-edge treatments for various medical issues. We continually invest in our team, technology, and processes to guarantee the delivery of superior products and services to our patients and partners. The Company expects to initiate a Phase 1 trial for its leading candidate Austin Biosciences-1103 in Q1, 2024 or earlier. Pre-clinical development is also underway for multiple product candidates in their pipeline.